|
1. Biologie
|
|
|
|
Using the laws of nature to predict tumour growth [The Institute of Cancer Research]
|
|
|
|
|
|
We
often think of cancers as being the chaotic and uncontrolled growth of
cells within the body. But increasing evidence is now pointing to the
fact that cancer evolution is often highly ordered and can even be
explained by a straightforward mathematical rule. This rule is important
because it hugely simplifies our view of how cancers evolve.
|
|
|
|
|
3.1 Tabac
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.2 Pharma
|
|
|
|
Incyte Falls on Jakafi Solid-Tumor Setback [TheStreet]
|
|
|
|
|
|
In
solid tumors, Incyte continues to develop an experimental cancer
immunotherapy drug, epacadostat, in combination with popular checkpoint
inhibitors. The importance of the company's epacadostat clinical program
grows now that Jakafi's solid-tumor ambitions have been shelved.
|
|
|
|
|
|
|
Incyte to stop pancreatic cancer drug trial [Reuters]
|
|
|
|
|
|
Jakafi,
the company's biggest revenue generator, is approved to treat patients
with polycythemia vera, a bone marrow disorder; and mylofibrosis, a type
of blood cancer. The drug raked in net product revenue of $601 million
in 2015, a 68 percent jump from a year earlier.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
FDA designated a record number of orphan drugs last year [STAT]
|
|
|
|
|
|
Orphan
drugs allow drug makers to benefit from seven years of marketing
exclusivity awarded by Congress. The FDA faces increasing pressure to
approve these medicines, which are treatments for rare diseases that
afflict small but often vocal patient populations.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.4 Médico-éco
|
|
|
|
|
6.5 Médecines alternatives
|
|
|